Annette Wooller

High Wycombe, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Factors and their weight in reducing life expectancy in schizophrenia.

Factors and their weight in reducing life expectancy in schizophrenia.

Journal: Schizophrenia research

Published: December 13, 2021

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia.

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia.

Journal: Neuropsychiatric disease and treatment

Published: October 15, 2020

Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate.

Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate.

Journal: Comprehensive psychiatry

Published: October 09, 2020

The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia.

The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia.

Journal: BMC psychiatry

Published: August 13, 2020

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes.

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes.

Journal: Therapeutic advances in psychopharmacology

Published: April 29, 2020

Become the expert and embrace a positive attitude: communication strategies for discussing long-acting injectable antipsychotic treatment with patients living with schizophrenia

Become the expert and embrace a positive attitude: communication strategies for discussing long-acting injectable antipsychotic treatment with patients living with schizophrenia

Journal: Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata

Published: March 20, 2020

Treating Schizophrenia: Open Conversations and Stronger Relationships Through Psychoeducation and Shared Decision-Making.

Treating Schizophrenia: Open Conversations and Stronger Relationships Through Psychoeducation and Shared Decision-Making.

Journal: Frontiers in psychiatry

Published: December 19, 2019

Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?

Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?

Journal: Psychological medicine

Published: June 05, 2018

Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia.

Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia.

Journal: International clinical psychopharmacology

Published: March 02, 2018

Showing 1-9 of 9

Last Updated: 09/26/2026